secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001213900-26-016496
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profusa signs exclusive worldwide license with Mayo Clinic for oxygen monitoring and CLTI
--------------------------------------------------------------------------------

- Profusa granted exclusive worldwide license from Mayo for patent rights in continuous oxygen measurement and Critical Limb-Threatening Ischemia (CLTI).
- Collaboration to support U.S. commercialization of Lumee wearable continuous tissue oxygen monitoring for critical limb ischemia.
- Potential new indications include cardiovascular, renal, multi-organ, and orthopedic postoperative perfusion monitoring.
- Profusa CEO notes over $100M invested in Lumee; Mayo retains financial interest for not-for-profit mission.
- Financial terms include royalties on net sales, milestone payments, and share of sublicense income.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/0001213900-26-016496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390026016496/ea0277026-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-016496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer